Resultados de Búsqueda
Given the evidence that the benefits of one of the bisphosphonates (alendronate) may continue for several years after the end of treatment, the Committee recommends that research should be carried ...
NICE
National Institute for Health and Clinical Excellence (NICE)
The Committee recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.
ver más ... 2018Given the evidence that the benefits of one of the bisphosphonates (alendronate) may continue for several years after the end of treatment, the Committee recommends that research should be carried ...
NICE
National Institute for Health and Clinical Excellence (NICE)
The Committee recommends research into the long-term effects of bisphosphonates on bone quality, given the inhibitory effects on bone resorption of these drugs.
ver más ... 2018Leadless cardiac pacemaker implantation is not recommended for patients with bradyarrhythmias.
NICE
National Institute for Health and Clinical Excellence (NICE)
Evidence on the safety of leadless cardiac pacemaker implantation for bradyarrhythmias shows that there are serious but well-recognised complications. The evidence on efficacy is inadequate in quantity and quality: - For people who can have conventional cardiac pacemaker implantation, leadless pacemakers should only be used in the context of research. - For people in whom a conventional cardiac pacemaker implantation is contraindicated following a careful risk assessment by a ...
ver más ... 2018Vandetanib is not recommended, within its marketing authorisation, for treating aggressive and symptomatic medullary thyroid cancer in adults with unresectable, locally advanced or metastatic ...
NICE
National Institute for Health and Clinical Excellence (NICE)
Vandetanib and cabozantinib are the only systemic treatment options for unresectable, locally advanced or metastatic medullary thyroid cancer. Best supportive care is the only other available option for people who cannot have vandetanib or cabozantinib. Clinical trial evidence suggests that vandetanib may delay disease progression compared with best supportive care, but the benefit is uncertain. The evidence about whether vandetanib increases the overall length of time people live is ...
ver más ... 2018Lenvatinib and sorafenib are recommended as options for treating progressive, locally advanced or metastatic differentiated thyroid cancer (papillary, follicular or Hürthle cell) in adults whose ...
NICE
National Institute for Health and Clinical Excellence (NICE)
This recommendation is not intended to affect treatment with lenvatinib or sorafenib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop. Lenvatinib and sorafenib (tyrosine kinase inhibitors) are the only treatment options for progressive, locally advanced ...
ver más ... 2018